Mouse CD158e1 Antibody | anti-CD158e1 antibody

Mouse Anti-Human CD158e1-UNLB

Cat. Num. AAA670602

• Applications: Flow Cytometry, Functional Assay, Immunohistochemistry, Immunocytochemistry, Immunoprecipitation
• Synonyms: CD158e1; Mouse Anti-Human CD158e1-UNLB; NKB1; p70; KIR; 3DL1; KIR3DL1; KIR3D; NKAT3; anti-CD158e1 antibody

• Host: Mouse
• Isotype: IgG1kappa
• Clone Number: DX9
• Specificity: Human/Baboon CD158e1
• Concentration: 0.1 mg/mL (varies by lot)

• Applicable Applications for anti-CD158e1 antibody: Flow Cytometry (FC/FACS), Immunohistochemistry (IHC) Formalin/ Paraffin, Immunocytochemistry (ICC), Immunoprecipitation (IP), Blocking (BL)
• Application Notes: Flow Cytometry - Quality tested; Immunohistochemistry-Frozen Sections - Reported in literature; Immunohistochemistry-Paraffin Sections - Reported in literature; Immunocytochemistry - Reported in literature; Immunoprecipitation - Reported in literature; Blocking - Reported in literature
• Immunogen: Human NK clone VL186-1 (CD3-, CD16+, CD56+)
• Buffer Formulation: Supplied in borate buffered saline, pH 8.2; No preservatives or amine-containing buffer salts added
• Isotype Control: Mouse IgG1-UNLB
• Preparation and Storage: Store at 2-8 degree C

Testing Data

Related Product Information for anti-CD158e1 antibody

CD158e1 is a 70 kDa transmembrane glycoprotein and a killer cell immunoglobulin (Ig)-like receptor (KIR) that is expressed on a subset of natural killer cells and T cells. The monoclonal antibody DX9 is expressed on a subset of CD3-, CD56+ NK cells isolated from peripheral blood at varying levels (<0.1% to 61%) among individuals but not on thymocytes, B lymphocytes, granulocytes, or monocytes. Interactions with CD158e1 and certain MHC HLA-B antigens on a target cell inhibits cytotoxicity, possibly preventing target cell lysis and death. KIR and MHC class I interactions may regulate NK and T cell response to antigen stimulation.

References

1. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. 1994;180:537-43. (Immunogen, Block, FC, IP)
2. Schleinitz N, Cognet C, Guia S, Laugier-Anfossi F, Baratin M, Pouget J, et al. Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies. Arthritis Rheum. 2008;58:3216-23. (FC, IHC-FS)
3. Hisashi Y, Yamada K, Kuwaki K, Tseng Y, Dor FJ, Houser SL, et al. Rejection of cardiac xenografts transplanted from alpha 1,3-galactosyltransferase gene-knockout (GalT-KO) pigs to baboons. Am J Transplant. 2008;8:2516-26. (IHC-PS, Baboon Reactivity)
4. Purdy AK, Alvarez Arias DA, Oshinsky J, James AM, Serebriiskii I, Campbell KS. The AP-2 clathrin adaptor mediates endocytosis of an inhibitory killer cell Ig-like receptor in human NK cells. J Immunol. 2014;193:4675-83. (FC, IP, ICC)
5. Söderström K, Corliss B, Lanier LL, Phillips JH. CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells. J Immunol. 1997;159:1072-5. (Block)
6. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol. 1995;155:2306-10. (FC)
7. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739-51. (FC, Block)
8. Bakker AB, Phillips JH, Figdor CG, Lanier LL. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gammadelta T cells, and antigen-specific CTL. J Immunol. 1998;160:5239-45. (FC, Block)
9. Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol. 2002;168:5047-57. (FC, IP, Block)